[1] Yelizaveta T, Albert D, Shanmugam N, et al. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription [J]. Cancer Res, 2006, 66(19): 9609-9616. [2] Hung C, Harvey B. Protein kinase C and guanosine triphosphate combine to potentiate calcium-dependent membrane fusion driven by annexin 7 [J]. J Biol Chem, 2002, 277(28): 25217-25225. [3] Hsu PI, Huang MS, Chen HC, et al. The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer [J]. J Surg Oncol, 2008, 97(7):609-614. [4] Srivastava M, Torosyan Y, Raffeld M, et al. ANXA7 expression represents hormone-relevant tumor suppression in different cancers [J]. Int J Cancer, 2007, 121(12):2628-2636. [5] Srivastava M, Bubendorf L, Raffeld M, et al. Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients [J]. Clin Cancer Res, 2004,10 (7):2344–2350. [6] Monastyrskaya K, Babiychuk EB, Draeger A. The annexins: spatial and temporal coordination of signaling events during cellular stress [J]. Cell Mol Life Sci, 2009, 66(16):2623-2642. [7] Mussunoor S, Murray GI. The role of annexins in tumour development and progression [J]. J Pathol, 2008, 216(2):131-140. [8] Hayes MJ, Longbottom RE, Evans MA, et al. Annexinopathies [J].Subcell Biochem, 2007, 45(3):1-28. [9] Hunter T. Oncoprotein networks [J]. Cell, 1997, 88(3):333-346. [10] Hartwell L, Kastan K. Cell cycle control and cancer [J]. Science, 1994, 266(5192): 1821-1828. [11]Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age [J]. Cell, 1994, 79(4):573-582. [12]Jack T, Weinberg R. Cell-cycle control and its watchman [J]. Nature, 1996, 381(6584):643-644. [13] Goyal L. Cell death inhibition: keeping caspases in check [J]. Cell, 2001, 104(6):805-808.
|